• First patient safely dosed with RC220 + doxorubicin combination
• No treatment-related dose-limiting side effects observed
• Trial open-label, will be conducted across multiple sites in Australia, Hong Kong and South Korea

Race Oncology Ltd is pleased to announce the successful and safe combination dosing of the first patient with RC220 plus doxorubicin in its Phase 1 clinical trial in advanced solid tumour patients. The patient was treated at the study's lead trial site, Southside Cancer Care Centre, Miranda, NSW. No treatment-related dose-limiting adverse side effects were observed. This follows the first patient being successfully dosed with RC220 alone and the activation of additional trial sites in Australia, Hong Kong and South Korea. The Phase 1 trial will use a Bayesian design, enabling greater trial flexibility and speed than previous approaches. In stage 1, ascending doses of RC220 will be used to determine the safety, tolerability, pharmacokinetics and maximum tolerated combined dose of RC220 in combination with doxorubicin in up to 33 patients. Effects on a range of clinical biomarkers including m6A RNA will also be examined. After interim analysis, the optimal dosage will be assessed in an additional 20 patients in Stage 2 for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals.

Race remains excited with the progress of RC220 in the clinic and its potential to offer an improved treatment option for the many patients at risk of cardiotoxicity related to doxorubicin therapy.